Analytical tools for capital optimization, healthcare financial modeling, and competitive benchmarking — integrated with real-world data from major healthcare companies.
Normalize any capital return to a 365-day annualized yield for cross-instrument comparison.
Model available capital buffer net of operational overhead across a defined deployment window.
Months to recover fixed costs given revenue and variable cost structure.
Revenue cycle efficiency metric — measures speed of cash conversion from patient services to collected revenue. Industry benchmark: <50 days.
Percentage of net revenue collected vs. expected after contractual adjustments. Top-performing health systems: 96–98%.
Evaluate whether a hospital service line is contributing positively to organizational margin.
Benchmark against major health system performance. HCA 2025 adj. EBITDA margin: ~20.6%.
Model the revenue delta from a 1% shift in commercial vs. Medicaid volume — the most significant revenue lever in hospital strategy.
Estimate internal rate of return for a capital investment with uniform annual cash flows.
Financial performance analysis of five major publicly-traded healthcare companies — sourced from SEC filings, company press releases, and earnings reports. Statistical benchmarking applied to key financial metrics.
HCA Healthcare (NYSE: HCA) is the largest for-profit hospital operator in the U.S., with 186 hospitals and 2,400+ ambulatory sites. Revenue grew from $70.6B (2024) to $75.6B (2025) — a 7.1% increase driven by same-facility admission growth and state supplemental payment program approvals in Tennessee and other markets.
Adj. EBITDA grew 12.1% year-over-year to $15.6B, reflecting significant operational leverage. Net income of $6.78B ($28.33/diluted share) significantly outpaced the prior year's $5.76B ($22.00/share). The company provided 2026 guidance reflecting continued growth, supported by outpatient surgical volume expansion and labor cost normalization.
$15.6B / $75.6B = 20.6%$6.78B / $75.6B = 9.0%(75.6/58.7)^(1/4) - 1 = 6.5%(15.6-13.9)/13.9 = 12.2%
UnitedHealth Group (NYSE: UNH) is the largest U.S. health insurer and healthcare services company, comprising UnitedHealthcare (insurance) and Optum (care delivery and analytics). 2024 revenues reached $400.3B — the highest of any healthcare company in the world.
Revenue grew from $371.6B (2023) to $400.3B (2024), led by strong Optum expansion and UnitedHealthcare membership growth. Adjusted operating income was $34.4B (8.6% margin). The 2024 results absorbed an estimated $0.75/share impact from the Change Healthcare cyberattack. Note: UNH reported Q1 2025 revenues of $100.8B (+9.1% YoY).
$34.4B / $400.3B = 8.6%(400.3/287.6)^(1/3) - 1 = 11.6%$100.8B × 4 = ~$403B annualized
CVS Health (NYSE: CVS) operates pharmacy, PBM (Caremark), and managed care (Aetna) segments. 2024 revenues reached $372.8B but operating performance was pressured by elevated medical costs in the Health Care Benefits segment — particularly Medicare Advantage utilization and adverse development from 2024 star ratings.
Operating income declined from $13.7B (2023) to $8.5B (2024) — a 38% drop — primarily from Aetna margin compression. Adjusted EPS fell from $8.85 to $5.42. Q1 2025 showed signs of recovery (+58% YoY adj. EPS), suggesting Medicare Advantage improvements are beginning to flow through. CVS's diversified model (PBM + pharmacy + insurance) provides structural resilience.
$8.5B / $372.8B = 2.3%(8.5-13.7)/13.7 = -38%Adj. EPS $2.25 vs. $1.31 prior year = +71.8%
Elevance Health (NYSE: ELV) — formerly Anthem — is one of the largest U.S. managed care organizations serving 45M+ members across commercial, Medicare, and Medicaid. 2024 operating revenue reached $175.2B, with operating gain of $6.2B despite Medicaid headwinds.
Q4 2024 benefit expense ratio rose 320 bps to 92.4%, reflecting Medicaid medical cost trends. Operating gain declined to $0.2B in Q4 2024 vs. $0.8B prior year. However, Q1 2025 showed strong recovery — revenue +15% YoY to $48.8B, driven by Medicare Advantage growth, CarelonRx, and premium yield improvements. CarelonRx (PBM/specialty pharmacy) is emerging as a major earnings diversifier.
$6.3B / $175.2B = 3.6%($48.8B - $42.3B) / $42.3B = 15.4%88.5% (+150bps YoY)
Cigna Group (NYSE: CI) delivered the strongest earnings trajectory among major payers in 2025. Net income of $6.0B exceeded the $3.4B reported in 2024 (which included a one-time non-cash investment loss). Adjusted income from operations grew to $8.0B vs. $7.7B in 2024.
Q4 2025 adjusted revenues rose 10% YoY to $72.5B — outperforming peers. Cigna's PBM-heavy model through Evernorth (Express Scripts) and its lean managed care exposure contributed to superior adjusted earnings momentum relative to CVS and Elevance, both of which faced utilization pressure. Cigna and UnitedHealth Group hold the two largest health insurance market shares.
($6.0B - $3.4B) / $3.4B = +76.5%$29.84 vs. $28.70 prior year = +4.0%+10% YoY = industry-leading
Benchmarks for hospital and health system financial performance. Compare your organization's metrics.
Key performance indicators for managed care organizations and health insurance operations.
Capital deployment and return benchmarks applicable across healthcare and financial operations.
Approximate Medicare base reimbursement for high-volume service lines. Not investment advice.
| DRG | Description | Approx. Base |
|---|---|---|
| 470 | Major Joint Replacement | ~$18–22K |
| 291 | Heart Failure w/ MCC | ~$17–21K |
| 247 | PCI w/ Drug Eluting Stent | ~$28–35K |
| 065 | Cerebral Infarction w/ MCC | ~$23–28K |
| 003 | ECMO / Trach w/ MV 96hrs | ~$160–195K |
| 190 | COPD w/ MCC | ~$10–13K |